Tagrisso (osimertinib) is a prescription medication approved for the treatment of certain types of non-small cell lung cancer (NSCLC) [1]. It is available in tablet form [2].
Should you break Tagrisso tablets?
It is not recommended to cut or crush Tagrisso tablets [3]. The medication is designed to be swallowed whole [3]. Tampering with the tablets may affect how the drug is absorbed and works in the body [3]. Always follow your doctor's instructions regarding how to take your medication [1].
How is Tagrisso usually prescribed?
Tagrisso is typically prescribed as a once-daily oral tablet [2]. The standard dosage for adults is 80 mg [2]. Your doctor will determine the correct dosage for you based on your medical condition and response to treatment [1].
What if I miss a dose of Tagrisso?
If you miss a dose of Tagrisso, take it as soon as you remember, unless it is close to your next scheduled dose [2]. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule [2]. Do not take two doses at the same time to make up for a missed dose [2].
How does Tagrisso work?
Tagrisso targets specific mutations in the epidermal growth factor receptor (EGFR) gene that drive certain types of NSCLC [1]. It works by blocking the signals that promote cancer cell growth [1].
What are the side effects of Tagrisso?
Common side effects of Tagrisso can include diarrhea, rash, dry skin, nail problems, and mouth sores [1]. More serious side effects can also occur, so it is important to discuss any concerns with your healthcare provider [1].
What is the patent status for Tagrisso?
Drug patents protect the exclusive rights to a drug for a certain period. Information on Tagrisso's patent status and potential future generic competition can be found on specialized drug patent websites [4].
How does Tagrisso compare to other EGFR inhibitors?
Tagrisso is considered a third-generation EGFR tyrosine kinase inhibitor (TKI). It is often used when other EGFR TKIs have not been effective or have led to resistance mutations [1]. Other EGFR inhibitors include gefitinib and erlotinib [5].
Sources:
[1] https://www.tagrisso.com/
[2] https://www.tagrisso.com/how-to-take-tagrisso
[3] https://www.tagrisso.com/frequently-asked-questions
[4] https://drugpatentwatch.com/
[5] https://www.cancer.org/cancer/types/lung-cancer/treating/targeted-therapy.html